Current state of cell therapies for breast cancer
N Gautam, KM Elleson, G Ramamoorthi… - The Cancer …, 2022 - journals.lww.com
Metastatic breast cancer (BC) is an aggressive form of cancer and is an absolute challenge
to treat. This review discusses the standard treatments available for metastatic BC. It further …
to treat. This review discusses the standard treatments available for metastatic BC. It further …
[HTML][HTML] High tumor mutational burden (TMB) identifies a microsatellite stable pancreatic cancer subset with prolonged survival and strong anti-tumor immunity
E Karamitopoulou, A Andreou, AS Wenning… - European journal of …, 2022 - Elsevier
Aim Tumor mutational burden (TMB: somatic mutations per megabase, mut/Mb) predicts the
efficacy of immunotherapy. Here, we link TMB levels with the activation of immune pathways …
efficacy of immunotherapy. Here, we link TMB levels with the activation of immune pathways …
[HTML][HTML] Intratumoral delivery of dendritic cells plus anti-HER2 therapy triggers both robust systemic antitumor immunity and complete regression in HER2 mammary …
G Ramamoorthi, K Kodumudi, C Snyder… - … for Immunotherapy of …, 2022 - ncbi.nlm.nih.gov
Background Human epidermal growth factor receptor 2 (HER2) targeted antibodies in
combination with chemotherapy has improved outcomes of HER2 positive (pos) breast …
combination with chemotherapy has improved outcomes of HER2 positive (pos) breast …